These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

676 related articles for article (PubMed ID: 8786624)

  • 1. [In vitro antibacterial activity of a new parenteral penem, sulopenem].
    Yoshida T; Tateda E; Hiramatsu K; Yokota T
    Jpn J Antibiot; 1996 Apr; 49(4):324-37. PubMed ID: 8786624
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sulopenem: An Intravenous and Oral Penem for the Treatment of Urinary Tract Infections Due to Multidrug-Resistant Bacteria.
    Zhanel GG; Pozdirca M; Golden AR; Lawrence CK; Zelenitsky S; Berry L; Schweizer F; Bay D; Adam H; Zhanel MA; Lagacé-Wiens P; Walkty A; Irfan N; Naber K; Lynch JP; Karlowsky JA
    Drugs; 2022 Apr; 82(5):533-557. PubMed ID: 35294769
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro activity and beta-lactamase stability of a new penem, CGP 31608.
    Neu HC; Chin NX; Neu NM
    Antimicrob Agents Chemother; 1987 Apr; 31(4):558-69. PubMed ID: 3496845
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [In vitro and in vivo activities of sulopenem compared with those of imipenem and cephalosporins].
    Nagashima M; Goto S; Yoshida T; Matsunaga T; Shimohira H; Ogawa M
    Jpn J Antibiot; 1996 Apr; 49(4):303-23. PubMed ID: 8786623
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Antibacterial activity of sulopenem, a new parenteral penem antibiotic].
    Inoue E; Komoto E; Taniyama Y; Mitsuhashi S
    Jpn J Antibiot; 1996 Apr; 49(4):338-51. PubMed ID: 8786625
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [In vitro and in vivo antibacterial activities of sulopenem, a new penem antibiotic].
    Komoto A; Otsuki M; Nishino T
    Jpn J Antibiot; 1996 Apr; 49(4):352-66. PubMed ID: 8786626
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cefpodoxime proxetil, its in vitro antibacterial activity, affinity to bacterial penicillin-binding proteins, and synergy of bactericidal activity with serum complement and mouse-cultured macrophages.
    Yokota T; Suzuki E; Arai K
    Drugs Exp Clin Res; 1988; 14(8):495-500. PubMed ID: 3073932
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Review of the in vitro spectrum of activity of imipenem.
    Jones RN
    Am J Med; 1985 Jun; 78(6A):22-32. PubMed ID: 3890537
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro and in vivo antibacterial activities of CS-807, a new oral cephalosporin.
    Utsui Y; Inoue M; Mitsuhashi S
    Antimicrob Agents Chemother; 1987 Jul; 31(7):1085-92. PubMed ID: 3310868
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (1996). I. Susceptibility distribution].
    Kumamoto Y; Tsukamoto T; Hirose T; Yokoo A; Shigeta S; Takahashi T; Shiraiwa Y; Ogiwara M; Yoshida H; Imafuku Y; Murai M; Watanabe K; Uchida H; Kobayashi Y; Matsuda S; Fujime M; Fujita K; Igari J; Oguri T; Yamaguchi K; Matsumoto T; Kashitani F; Kaku M; Ooe H; Mochida C
    Jpn J Antibiot; 1998 Feb; 51(2):69-111. PubMed ID: 9575437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Post-marketing surveillance of antibacterial activities of cefozopran against various clinical isolates--II. Gram-negative bacteria].
    Igari J; Oguri T; Hiramatsu N; Akiyama K; Koyama T
    Jpn J Antibiot; 2003 Oct; 56(5):458-96. PubMed ID: 14692381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro and in vivo evaluation of Ro 09-1428, a new parenteral cephalosporin with high antipseudomonal activity.
    Arisawa M; Sekine Y; Shimizu S; Takano H; Angehrn P; Then RL
    Antimicrob Agents Chemother; 1991 Apr; 35(4):653-9. PubMed ID: 1906261
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (1997). I. Susceptibility distribution].
    Kumamoto Y; Tsukamoto T; Hirose T; Yokoo A; Fujime M; Fujita K; Shigeta S; Watanabe J; Igari J; Ogiwara M; Ishibashi K; Oguri T; Yoshida H; Imafuku Y; Yamaguchi K; Matsumoto T; Kashitani F; Murai M; Ooe H; Nishikawa M; Watanabe K; Kobayashi Y; Uchida H; Oka T; Mochida C
    Jpn J Antibiot; 1999 Feb; 52(2):93-129. PubMed ID: 10221177
    [TBL] [Abstract][Full Text] [Related]  

  • 14. State of penicillin-binding proteins and requirements for their bactericidal interaction with beta-lactam antibiotics in Serratia marcescens highly resistant to extended-spectrum beta-lactams.
    Gunkel AG; Hechler U; Martin HH
    J Gen Microbiol; 1991 Feb; 137(2):243-52. PubMed ID: 2016583
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Target affinities of faropenem to and its impact on the morphology of gram-positive and gram-negative bacteria.
    Dalhoff A; Nasu T; Okamoto K
    Chemotherapy; 2003 Jul; 49(4):172-83. PubMed ID: 12886052
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from urinary tract infections (1993). I. Susceptibility distribution].
    Kumamoto Y; Hirose T; Tanaka N; Hikichi Y; Shigeta S; Shiraiwa Y; Kameoka H; Yoshida H; Tazaki H; Iri H
    Jpn J Antibiot; 1995 Nov; 48(11):1757-87. PubMed ID: 8558757
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MEN 10700, a new penem antibiotic: in-vitro activity and its correlation with beta-lactamase stability, PBP affinity and diffusion through the bacterial cell wall.
    Fontana R; Altamura M; Arcamone F; Mazzariol A; Morandotti G; Sperning R; Cornaglia G
    J Antimicrob Chemother; 1998 May; 41(5):513-25. PubMed ID: 9630405
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro activity of HRE 664, a penem antibiotic.
    Chin XN; Neu HC
    Diagn Microbiol Infect Dis; 1990; 13(6):509-16. PubMed ID: 2279381
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro activity of CP-65,207, a new penem antimicrobial agent, in comparison with those of other agents.
    Gootz T; Retsema J; Girard A; Hamanaka E; Anderson M; Sokolowski S
    Antimicrob Agents Chemother; 1989 Aug; 33(8):1160-6. PubMed ID: 2679370
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro and in vivo antibacterial activities of FK037, a new parenteral cephalosporin.
    Nishino T; Otsuki M; Hatano K; Nishihara Y
    Chemotherapy; 1994; 40(3):167-82. PubMed ID: 8205935
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.